Sugi Predict

Sugi Predict / Targets / ITGA5

ITGA5

Integrin alpha-5 · P08648 · ITGA5 on Sugi Atlas →

35,581 patent compounds predicted against ITGA5, 22,471 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL852225 SCHEMBL852225 0.62 16/20
SCHEMBL1121309 SCHEMBL1121309 0.53 16/20
SCHEMBL852636 SCHEMBL852636 0.54 15/20
SCHEMBL853781 SCHEMBL853781 0.47 14/20
SCHEMBL853586 SCHEMBL853586 0.49 13/20
SCHEMBL1069663 SCHEMBL1069663 0.47 13/20
SCHEMBL852473 SCHEMBL852473 0.46 12/20
SCHEMBL853153 SCHEMBL853153 0.50 11/20
SCHEMBL852838 SCHEMBL852838 0.45 11/20
SCHEMBL451422 SCHEMBL451422 0.44 11/20
SCHEMBL1121063 SCHEMBL1121063 0.54 8/20
SCHEMBL244675 SCHEMBL244675 0.47 8/20
SCHEMBL538331 SCHEMBL538331 0.47 8/20
Cilengitide Cilengitide (SCHEMBL34082) 0.68 7/20
SCHEMBL852226 SCHEMBL852226 0.66 7/20
SCHEMBL1123223 SCHEMBL1123223 0.55 7/20
SCHEMBL852681 SCHEMBL852681 0.51 7/20
SCHEMBL287604 SCHEMBL287604 0.76 6/20
SCHEMBL296647 SCHEMBL296647 0.71 6/20
SCHEMBL285998 SCHEMBL285998 0.70 6/20

Clinical trials — most relevant to ITGA5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cilengitide in Treating Patients With Metastatic Prostate Cancer PHASE2COMPLETED
Cilengitide in Treating Patients With Prostate Cancer PHASE2COMPLETED
2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD PHASE2COMPLETED
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I PHASE1WITHDRAWN
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 PHASE1RECRUITING
Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma PHASE1COMPLETED
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma EARLY_PHASE1UNKNOWN
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients EARLY_PHASE1COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction EARLY_PHASE1UNKNOWN
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) nanCOMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer nanCOMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types nanCOMPLETED
Efferocytosis and Genomic Polymorphism in Autoimmune Diseases nanUNKNOWN
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
Eosinophil Induced Remodelling in Asthma nanCOMPLETED
The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer nanUNKNOWN
68Ga-NODAGA-RGD PET in Patients With an Occluded Coronary Artery nanUNKNOWN
Integrin αvβ6-targeted PET in Malignant Tumors nanRECRUITING
Clinical Study of 18F-FAPI-RGD in Breast Tumors nanCOMPLETED
CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer nanRECRUITING
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ITGA5 binder may also engage these)

ProteinNameSimilarity
P11688 — 1.000 P11688 →
ITGA2B Integrin alpha-IIb 0.999 landscape →
Q13683 — 0.994 Q13683 →
F1MMS9 — 0.990 F1MMS9 →
O75578 — 0.990 O75578 →
P26006 — 0.990 P26006 →
ITGAL Integrin alpha-L 0.989 landscape →
Q27977 — 0.988 Q27977 →
Q62470 — 0.988 Q62470 →
Q9QUM0 — 0.988 Q9QUM0 →
P53711 — 0.987 P53711 →
P38570 — 0.986 P38570 →
Q3V0T4 — 0.986 Q3V0T4 →
P24063 — 0.983 P24063 →
Q63258 — 0.982 Q63258 →
Q9QYE7 — 0.982 Q9QYE7 →
P17852 — 0.982 P17852 →
Q13349 — 0.981 Q13349 →
B8JK39 — 0.979 B8JK39 →
ITGAM Integrin alpha-M 0.979 landscape →
Q61738 — 0.979 Q61738 →
Q06274 — 0.979 Q06274 →
ITGA8 Integrin alpha-8 [Cleaved into: Integrin alph 0.977 landscape →
Q9QXH4 — 0.976 Q9QXH4 →
P43406 — 0.976 P43406 →
Q13797 — 0.975 Q13797 →
P20702 — 0.975 P20702 →
P61625 — 0.975 P61625 →
Q8BNJ2 — 0.975 Q8BNJ2 →
A2ARA8 — 0.974 A2ARA8 →